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In owl monkeys, a retrotransposition event replaced the gene encoding the retroviral restriction factor TRIM5α with one encoding TRIMCyp, a
fusion between the RING, B-box 2 and coiled-coil domains of TRIM5 and cyclophilin A. TRIMCyp restricts human immunodeficiency virus
(HIV-1) infection by a mechanism dependent on the interaction of the cyclophilin A moiety and the HIV-1 capsid protein. Here, we show that
infection by retroviruses other than HIV-1 can be restricted by TRIMCyp, providing an explanation for the evolutionary retention of the TRIMCyp
gene in owl monkey lineages. The TRIMCyp-mediated block to HIV-1 infection occurs before the earliest step of reverse transcription. TRIMCyp-
mediated restriction involves at least two functions: (1) capsid binding, which occurs most efficiently for trimeric TRIMCyp proteins that retain
the coiled-coil and cyclophilin A domains, and (2) an effector function that depends upon the B-box 2 domain.
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Following entry into cells, some retroviruses encounter
dominant blocks to infection that act prior to reverse transcription
(Munk et al., 2002; Hofmann et al., 1999; Cowan et al., 2002;
Besnier et al., 2002; Hatziioannou et al., 2003). Human
immunodeficiency virus (HIV-1), for example, is blocked in
the cells of most Old World monkeys (Hofmann et al., 1999;
Song et al., 2005). Infection by the simian immunodeficiency
virus of macaques (SIVmac) encounters similar restrictions in
New World monkeys (Hofmann et al., 1999). These restrictions
are mediated by TRIM5α, a tripartite motif protein with a RING,
B-box 2 and coiled-coil (CC) domain, as well as a carboxy-
terminal B30.2(SPRY) domain (Stremlau et al., 2004; Keck-
esova et al., 2004; Hatziioannou et al., 2004a; Yap et al., 2004;
Perron et al., 2004; Nisole et al., 2005). The TRIM5α B30.2⁎ Corresponding author. Dana-Farber Cancer Institute, 44 Binney Street-JFB
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doi:10.1016/j.virol.2006.03.023domain is essential for retroviral restriction, and differences in
the potency of TRIM5α from different species map to this
domain (Sawyer et al., 2005; Stremlau et al., 2005; Nakayama et
al., 2005; Yap et al., 2005). The viral determinant of
susceptibility to TRIM5α-mediated restriction is the capsid
protein, which assembles into the capsid structure that surrounds
the viral genomic RNA and enzymes (Hatziioannou et al.,
2004b; Owens et al., 2003, 2004; Kootstra et al., 2003). These
results suggest that the TRIM5αB30.2 domainmay interact with
the capsid of the incoming virus, leading to a disruption of the
infection process through an unknown mechanism.
Owlmonkeys are an unusual NewWorldmonkey species that
exhibit restrictions to HIV-1 and not SIVmac (Hofmann et al.,
1999; Towers et al., 2003). Instead of TRIM5α, owl monkeys
express TRIMCyp, a protein that consists of the RING, B-box 2
and CC domains of TRIM5 fused with a carboxy-terminal
cyclophilin A (Cyp A) moiety (Sayah et al., 2004; Yap et al.,
2004). The TRIMCyp gene was generated by a retrotransposition
event involving the TRIM5 and Cyp A genes. Cyp A is known to
bind the HIV-1 p24 soluble capsid protein through recognition of
Fig. 1. TRIMCyp deletions and retroviral restriction. (A) The wild-type TRIMCyp protein is depicted in the top figure. The numbers of the amino acid residues at the
boundaries of the TRIMCyp domains are shown. The carboxyl terminus of the protein contains either a hemagglutinin (HA) epitope tag or a V5 tag. The regions
retained in each of the TRIMCyp mutants are depicted. The position of the C96A change is indicated. (B) HeLa and Cf2Th cells were transduced with pLenti or LPCX
vectors, respectively, expressing the indicated TRIMCyp proteins. The TRIMCyp proteins expressed in HeLa cells contain a carboxy-terminal V5 epitope tag; the
TRIMCyp proteins expressed in the Cf2Th cells contain a carboxy-terminal HA epitope tag. Cell lysates were Western blotted and probed with antibodies directed
against either the appropriate epitope tag (top panels) or β-actin (bottom panels). (C–F) HeLa cells expressing the wild-type and mutant TRIMCyp proteins or control
HeLa cells transduced with the empty pLenti vector, were challenged with the indicated amounts of HIV-1-GFP (C, D), SIVagm-GFP (E), or SIVmac-GFP (F). The
percentage of GFP-positive cells was determined by FACS. Similar results were obtained in three independent experiments. (G, H) Cf2Th cells expressing TRIMCyp
or transduced with the empty LPCX vector were challenged with increasing amounts of FIV-GFP (G) or EIAV-GFP (H). The percentage of GFP-positive cells was
determined by FACS. (I) HeLa cells stably expressing the wild-type and mutant TRIMCyp proteins were fixed and stained using a fluorescein isothiocyanate-
conjugated anti-HA antibody as described in Materials and methods. Representative confocal microscope images are shown.
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Fig. 1 (continued).
406 F. Diaz-Griffero et al. / Virology 351 (2006) 404–419a surface-exposed loop (Gamble et al., 1996; Luban et al., 1993).
Cyp A binding contributes to the efficiency of HIV-1 infection;
the mechanism of this enhancement is unknown, although the
prolyl isomerase activity of Cyp A has been suggested to modify
the conformation of the HIV-1 capsid protein (Bosco et al., 2002;
Bosco and Kern, 2004). Treatment of owl monkey cells with
cyclosporine A (CsA), which blocks cyclophilin A-HIV-1
capsid interactions, relieves the restriction to HIV-1 infection
in owl monkey cells (Towers et al., 2003). Thus, the interaction
of TRIMCyp with the HIV-1 capsid protein is apparently
important for the block to infection. TRIMCyp has been shown
to bind the monomeric HIV-1 p24 capsid protein (Gamble et al.,
1996; Luban et al., 1993). However, there is evidence suggesting
that the assembled capsid is the biologically relevant target for
TRIM5α and TRIMCyp interaction (Cowan et al., 2002;Forshey et al., 2005; Dodding et al., 2005). The TRIMCyp-
mediated block to HIV-1 infection can be abrogated by exposure
of owl monkey cells to HIV-1 virus-like particles that can
introduce mature, but not unprocessed, capsid structures into the
cytoplasm (Forshey et al., 2005). By contrast, expression of
monomeric HIV-1 capsid proteins in cells does not relieve
restriction (Dodding et al., 2005; Sebastian and Luban, 2005).
Here, we investigate retroviral restriction by TRIMCyp. We
study the level of the block with respect to the retroviral
infection cycle. We examine the range of lentiviruses
susceptible to TRIMCyp restriction and demonstrate that
infection by the SIV of African green monkeys (SIVagm) and
feline immunodeficiency virus (FIV) can be inhibited by
TRIMCyp. The role of each TRIMCyp domain in restriction
is studied, and mutant TRIMCyp proteins that efficiently bind
Fig. 1 (continued).
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Thus, TRIMCyp-mediated restriction involves both capsid-
binding and effector functions.
Results
Ability of wild-type and mutant TRIMCyp to restrict various
retroviruses
HIV-1 is the only virus that has currently been shown to
be restricted by TRIMCyp (Sayah et al., 2004; Nisole et al.,
2004). To examine whether TRIMCyp restriction might
extend to other retroviruses and to investigate the contribu-
tion of TRIMCyp domains to its antiviral function, weconstructed TRIMCyp mutants lacking the RING, B-box 2
and coiled coil domains, or the linker region between the
coiled coil and cyclophilin A (Fig. 1A). Several of these
mutants were expressed stably and efficiently in human
HeLa and canine Cf2Th cells (Fig. 1B). Cells were
challenged with VSV G-pseudotyped, GFP-expressing vec-
tors based on HIV-1, SIVmac, SIVagm, FIV and EIAV (Figs.
1C–H). The wild-type TRIMCyp potently inhibited infection
by HIV-1, SIVagm and FIV, but did not affect the efficiency
of SIVmac and EIAV infection. Thus, retroviruses other than
HIV-1 are susceptible to TRIMCyp-mediated restriction.
Deletion of the TRIMCyp RING domain diminished, but
did not eliminate, the inhibition of HIV-1 and SIVagm infection
(Table 1 and Figs. 1C and E). Deletion of the RING and B-box
Table 1
Effect of expression of TRIMCyp variants on HIV-1 infection
TRIMCyp variant %GFP-positive cells a
HeLa Cf2Th
Empty vector 70 (100%) 97 (100%)
TRIMCyp 10 (14%) 3 (3%)
TRIMCyp Δ93 34 (48%) 16 (16%)
TRIMCyp Δ128 80 (114%) 61 (62%)
TRIMCyp Δ245 50 (72%) 88 (91%)
TRIMCyp Δ310 ND 91 (94%)
ND = not determined.
a The percentage of GFP-positive cells after incubation with HIV-1-GFP is
shown. Numbers in parenthesis are normalized to the value of GFP-positive
cells seen in the control cells transduced with the empty vector.
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slight but reproducible inhibitory effect of the TRIMCyp Δ245
protein on HIV-1 infection of HeLa cells was observed; this
may be due to overexpression of cyclophilin A activity, which
has been suggested to be detrimental to HIV-1 infection in
some contexts (Hatziioannou et al., 2005; Sayah and Luban,
2004; Gatanaga et al., 2006). Expression of the TRIMCyp
Δ93, TRIMCyp Δ128 and TRIMCyp Δ245 constructs
resulted in partial inhibition of SIVagm infection, compared
with the wild-type TRIMCyp protein. Thus, the RING and B-
box 2 domains of TRIMCyp contribute to the efficiency of the
antiviral activity.
In the C96A TRIMCyp mutant, a cysteine residue that is
predicted to coordinate a zinc atom in the B-box 2 domain
is disrupted. TRIMCyp C96A stably expressed in HeLa cells
did not restrict HIV-1 when compared to wild-type
TRIMCyp (Fig. 1D). Thus, disruption of the B-box domain
by deletion (TRIMCyp Δ128) or by an individual amino
acid change (TRIMCyp C96A) impaired the ability of
TRIMCyp to restrict HIV (Figs. 1C and D), suggesting that
an intact B-box domain is required for efficient antiretroviral
activity.
We also analyzed the subcellular localization of wild-type
and mutant TRIMCyp proteins (Fig. 1I). Similar to TRIM5αrh,
TRIMCyp was located in the cytoplasm and also formed
cytoplasmic bodies. TRIMCyp Δ93 presented a diffuse
cytoplasmic staining pattern. Unlike TRIM5αrh Δ93 (Javan-
bakht et al., 2005), TRIMCyp Δ93 did not exhibit nuclear
localization or form nuclear bodies. TRIMCyp Δ128 formed
very unusual spiral-like structures in the perinuclear region.
TRIMCyp C96A exhibited a pattern of intracellular staining
similar to that of wild-type TRIMCyp. TRIMCyp Δ245 and
Δ310 were localized diffusely throughout the nucleus and
cytoplasm.
To evaluate the ability of the TRIMCyp mutants to interfere
with the antiretroviral activity of an endogenously expressed
TRIMCyp protein, the mutants were stably expressed in owl
monkey kidney (OMK) cells (Fig. 2A). The cells were
incubated with different amounts of HIV-1-GFP (Fig. 2B).
Expression of wild-type and Δ93 TRIMCyp proteins increased
the degree of HIV-1 restriction in these cells, whereas the
TRIMCyp Δ128 and Δ245 variants slightly decreased thelevel of HIV-1 restriction. Expression of the coiled-coil
domain of TRIMCyp (TRIMCyp CC(128–245)) in OMK
cells more potently relieved the restriction of HIV-1 infection
mediated by endogenous TRIMCyp (Fig. 2B). To confirm
these results, we stably coexpressed the coiled-coil domain of
TRIMCyp and wild-type TRIMCyp in Cf2Th cells (Fig. 2C).
Expression of the coiled-coil domain alone diminished the
antiretroviral activity of TRIMCyp (Fig. 2D). One possible
explanation for this dominant-negative activity is that the
interaction of the coiled-coil domain of TRIMCyp with wild-
type TRIMCyp disrupts the antiretroviral activity. To evaluate
the ability of these molecules to interact, we attempted to
coprecipitate the TRIMCyp coiled coil with wild-type
TRIMCyp (Fig. 2E). As expected, TRIMCyp interacted with
TRIMCyp CC(128–245), consistent with the observed dom-
inant negative activity.
Requirement for TRIMCyp interaction with the viral capsid for
restriction
We wished to confirm previous observations suggesting
that TRIMCyp interaction with the HIV-1 capsid is necessary
for restriction (Towers et al., 2003; Sayah et al., 2004; Nisole
et al., 2004; Chatterji et al., 2005) and to examine whether this
is true for TRIMCyp-mediated restriction of other viruses such
as SIVagm and FIV. HeLa cells expressing TRIMCyp or
transduced with the control pLenti vector were challenged
with either HIV-1-GFP or SIVagm-GFP in the presence or
absence of cyclosporine A (Figs. 3A and B). Similarly, Cf2Th
cells expressing TRIMCyp or transduced with the control
LPCX vector were challenged with FIV-GFP in the presence
or absence of cyclosporine A (Fig. 3C). Cyclosporine A,
which inhibits the binding of cyclophilin A to its substrates
(Luban et al., 1993), completely eliminated the TRIMCyp-
mediated restriction of HIV-1, SIVagm and FIV. Cyclosporine
A treatment also resulted in an increase in FIV infection in the
Cf2Th canine cells transduced with the control vector (Fig.
3C). These results support a model in which TRIMCyp must
bind to components of the targeted virus to achieve restriction
of infection.
To demonstrate the role of the viral capsid in susceptibility
to TRIMCyp-mediated restriction, OMK cells or control Cf2Th
cells were challenged with recombinant GFP-expressing
viruses with either wild-type HIV-1 or variant capsids (Figs.
3D and E). As previously reported (Towers et al., 2003), HIV-1
capsids with changes in glycine 89 or proline 90, which are
important for cyclophilin A binding (Gamble et al., 1996;
Vajdos et al., 1997; Yoo et al., 1997), were less susceptible
than the wild-type HIV-1 capsid to the restriction in OMK
cells. HIV-1 viruses with SIVmac capsid proteins (HIV(SCA))
were also restricted less than the wild-type HIV-1 in these
cells. Infection by SIVmac with an HIV-1 capsid (SIV (HCA-
p2)) was inefficient in the control Cf2Th cells; in the OMK
cells, infection by this virus was undetectable. These results
support the importance of the interaction of the cyclophilin A
moiety on TRIMCyp with the HIV-1 capsid for restriction of
infection.
Fig. 2. Dominant-negative effects of expression of TRIMCyp variants. (A) Owl monkey kidney (OMK) cells were transduced with pLenti vectors expressing the
indicated TRIMCyp variants with carboxy-terminal V5 epitope tags. Cell lysates were Western blotted with an antibody against the V5 epitope (top panel) or against
β-actin (bottom panel). (B) OMK cells expressing the indicated TRIMCyp variants or transduced with the empty pLenti vector were challenged with HIV-1-GFP and
GFP-positive cells were measured by FACS. The results of a typical experiment are shown; the experiment was repeated twice with similar results. (C, D) Cf2Th cells
were transduced with a pLenti vector expressing the coiled-coil domain of TRIMCyp with a V5 epitope tag. Afterwards cells were transduced with an LPCX vector
expressing HA-tagged wild-type TRIMCyp or with an empty LPCX vector. (C) Cells lysates were analyzed byWestern blot using antibodies against HA (upper panel),
against V5 (middle panel) and β-actin (lower panel). In panel D, the Cf2Th cells were incubated with HIV-1-GFP, and GFP-positive cells were measured by FACS.
Results of two experiments were similar, and the results of one experiment are shown. (E) 293T cells were cotransfected with the control pLPCX plasmid or a plasmid
encoding wild-type TRIMCyp-HA protein and a plasmid encoding TRIMCyp CC(128–245), which consists of the coiled-coil domain of TRIMCyp tagged with a V5
epitope. The 293T cells were lysed 36 h after transfection. Cell extracts were analyzed by Western blotting using antibodies against the V5 tag, HA tag or β-actin. Cell
lysates were used for immunoprecipitation (IP) by the anti-HA antibody. The precipitates were Western blotted (WB) with an anti-V5 antibody (bottom panel). Similar
results were obtained in three independent experiments.
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Fig. 3. Importance of capsid binding by the cyclophilin A moiety to TRIMCyp restriction. HeLa cells transduced with either the empty vector pLenti or a vector
expressing TRIMCyp were challenged with various amounts of HIV-1-GFP (A) or SIVagm-GFP (B) in the presence and absence of 5 μM cyclosporine A (CsA). (C)
Cf2Th cells expressing TRIMCyp or transduced with the empty LPCX vector were challenged with various amounts of FIV-GFP in the presence and absence of 5 μM
cyclosporine A (CsA). (D, E) OMK cells (D) and Cf2Th cells (E) were challenged with various amounts of HIV-1-GFP viruses containing the indicated capsids. In
addition, infections using a GFP-expressing HIV-1 vector containing the SIVmac capsid (HIV (SCA)) and SIVmac containing the HIV-1 capsid and p2 proteins (SIV
(HCA-p2)) (Owens et al., 2004) are shown. All viral titers were calculated based on HIV-1 p24 amounts with the exception of HIV (SCA) in which SIVmac p27 was
used. Similar results were obtained in three independent experiments.
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Because TRIMCyp restriction of HIV-1 can be relieved by
cyclosporine A treatment (Owens et al., 2004; Towers et al.,
2003), the timing of TRIMCyp action could be investigated.
HIV-1-GFP viruses were incubated with control Cf2Th cells
transduced with the LPCX vector or Cf2Th cells expressing
TRIMCyp, and cyclosporine A was added at various time
points. In some arms of the experiment, the lysosomotropic
agent ammonium chloride was added along with cyclosporine
A to prevent further virus entry into the cells (Seglen, 1983;Matlin et al., 1982; Aiken, 1997). The resulting level of
infection was determined by quantitating GFP-positive cells
(Fig. 4A). The results indicate that 62 and 78 percent of viruses
that enter the cells within the first or second hour, respectively,
of incubation are inhibited by TRIMCyp in a manner that is
not subsequently reversible by cyclosporine A. The half-life
of infectious viruses inside TRIMCyp-expressing cells is less
than 1 h.
We also measured the production of HIV-1 reverse
transcripts in Cf2Th cells expressing TRIMCyp or TRIM5αrh.
The infection of these cells was very inefficient compared with
411F. Diaz-Griffero et al. / Virology 351 (2006) 404–419that of control cells transduced with the LPCX vector (Fig.
4B). Measurement of HIV-1 reverse transcripts in these cells
by real-time PCR revealed that even the earliest product of
reverse transcription, strong-stop cDNA, was not synthesized
efficiently in cells expressing TRIMCyp or TRIM5αrh (Figs.
4C and D). Consistent with these results, strong-stop cDNA
was not observed in OMK cells incubated with HIV-1 virus
preparations (data not shown). Thus, TRIMCyp blocks HIV-1infection at an early, post-entry step, before reverse transcrip-
tion is initiated.
TRIMCyp oligomerization
Old World monkey TRIM5α proteins have been shown to
form trimers (Mische et al., 2005). To study the oligomerization
of wild-type TRIMCyp and TRIMCyp mutants, these proteins
were expressed transiently in 293Tcells. Cell lysates were cross-
linked with glutaraldehyde and then Western blotted. Fig. 5
shows that wild-type and RING- and B-box 2-deleted TRIMCyp
proteins formed trimers and higher-order oligomers. By contrast,
TRIMCyp Δ245, which is missing the coiled coil, and
TRIMCyp CC(128–245), which contains only the coiled-coil,
did not form oligomers efficiently. Thus, the TRIMCyp coiled
coil is necessary but not sufficient for trimer/oligomer formation.
The HA-tagged wild-type TRIMCyp protein was coex-
pressed transiently in 293T cells with V5-tagged wild-type and
mutant TRIMCyp proteins. Precipitation of the wild-type
TRIMCyp protein with an anti-HA antibody coprecipitated
TRIMCyp, TRIMCyp Δ93 and TRIMCyp Δ128 proteins, but
not the TRIMCypΔ245 protein (Fig. 6). These results support a
model in which the RING and B-box 2 domains are dispensable
for TRIMCyp self-association; by contrast, the coiled coil is
essential for efficient self-association.
TRIMCyp interaction with HIV-1 CA–NC complexes
To investigate the ability of TRIMCyp to interact with the
HIV-1 capsid, we incubated 293T cell lysates containing
TRIMCyp variants with HIV-1 CA–NC complexes assembled
in vitro. These CA–NC complexes have been shown by
cryoelectron microscopy to simulate closely the architecture of
the bona fide HIV-1 capsid (Ganser-Pornillos et al., 2004). After
incubation with TRIMCyp-containing lysates, the CA–NC
complexes were pelleted through 70% sucrose cushions, and the
pellets were analyzed for CA–NC and TRIMCyp proteins. Fig.
7A shows that TRIMCyp copellets with the HIV-1 CA–NCFig. 4. Early post-entry restriction of HIV-1 by TRIMCyp. (A) Cf2Th cells
expressing TRIMCyp or transduced with the control vector LPCX were
challenged with HIV-1-GFP. Cyclosporine A (CsA), with or without ammonium
chloride, was added at the indicated times after virus–cell incubation. The
ammonium chloride was added to cells (final concentration 40 mM) to block
entry mediated by the pH-dependent VSV G glycoprotein. The amount of HIV-
1-GFP used was sufficient to infect nearly all of the Cf2Th cells transduced with
the control LPCX vector. Similar results were obtained in three independent
experiments. The percentage of entering viruses that were restricted by
TRIMCyp in the period prior to the time at which cells were treated with
cyclosporine A and ammonium chloride was calculated using the formula
shown. The calculated percentage at each hourly time point is shown. (B–D)
Cf2Th cells stably expressing TRIMCyp or TRIM5αrh, or transduced with the
empty LPCX vector, were challenged with equal amounts of the HIV-1
luciferase reporter virus or a control virus without envelope glycoproteins
(Δenv). Luciferase activity in the cells was measured 48 h later. Infectivity was
expressed in relative light units (B). Similar infections were performed and HIV-
1 extrachromosomal DNA was extracted at 0 and 6 h post-infection. DNA
samples were used to detect strong-stop cDNA (C) and complete LTR copies (D)
per 6000 cell equivalents by real-time PCR. Similar results were obtained in
three independent experiments.
Fig. 6. Association of coexpressed wild-type and mutant TRIMCyp proteins.
293T cells were cotransfected with a plasmid encoding HA-tagged wild-type
TRIMCyp and a plasmid encoding V5-tagged wild-type or mutant TRIMCyp
proteins. The 293T cells were lysed at 36 h after transfection. Cell lysates were
Western blotted with antibodies against the V5 tag, HA tag or β-actin. Cell
lysates were used for immunoprecipitation (IP) by the anti-HA antibody. The
precipitates were Western blotted (WB) with an anti-V5 antibody (bottom
panel). Similar results were obtained in three independent experiments.
Fig. 5. Oligomerization of TRIMCyp. 293T cells were transiently transfected
with plasmids expressing wild-type TRIMCyp or the indicated mutants with V5
epitope tags. Cells were lysed 36 h after transfection and cross-linked with the
indicated concentrations of glutaraldehyde (GA). The cell lysates were
subsequently blotted with an anti-V5 antibody.
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by cyclosporine A. TRIMCyp proteins (TRIMCyp Δ93,
TRIMCyp Δ128, TRIMCyp Δ95–128, and TRIMCyp C96A)
lacking intact RING or B-box 2 domains interacted efficiently
with the CA–NC complexes (Figs. 7B and D). By contrast,
proteins consisting of the TRIMCyp cyclophilin A domain or
the cyclophilin A domain and the linker region did not
efficiently bind CA–NC complexes (Fig. 7B). The linker
region between the coiled coil and cyclophilin A domain was
not necessary for CA–NC association (TRIMCyp Δ232–310)
(Fig. 7D). The TRIMCyp coiled coil alone (TRIMCyp CC(128–245)) did not interact with the CA–NC complexes (Fig.
7C). These results suggest that both the coiled coil and
cyclophilin A moieties are important for efficient TRIMCyp
association with HIV-1 capsid complexes.
To determine whether TRIMCyp directly interacts with the
HIV-1 capsid, we expressed TRIMCyp as a thioredoxin fusion
protein in bacteria and incubated the purified protein with HIV-
1 CA–NC complexes assembled in vitro. Pure thioredoxin-
TRIMCyp bound the CA–NC complexes, and treatment with
cyclosporine A abolished this interaction (Fig. 7E). Only
minimal thioredoxin-TRIMCyp was found in the pellet in the
absence of added HIV-1 CA–NC complexes. Thus, TRIMCyp
directly associates with the HIV-1 capsid in a manner
independent of any eukaryotic proteins.
Discussion
New World monkeys of the genus Aotus, the owl or night
monkeys, are the only known primates to express TRIMCyp
(Ribeiro et al., 2005). The TRIMCyp gene apparently arose as a
result of a retrotransposition event involving the cyclophilin A
and TRIM5 genes (Sayah et al., 2004; Nisole et al., 2004). This
retrotransposition occurred after the divergence of owl monkeys
from other New World monkeys. TRIMCyp is maintained in all
Fig. 7. TRIMCyp binding to assembled HIV-1 capsids. 293T cells were transfected with wild-type and mutant TRIMCyp constructs tagged with V5 epitopes.
Thirty-six hours after transfection, cells were lysed and the lysates mixed with in vitro assembled HIV-1 CA–NC complexes. The mixtures were applied to a 70%
sucrose cushion. INPUT represents the mixtures analyzed byWestern blot before being applied to the 70% cushion. The INPUTmixtures were blotted for the V5 tag, the
HIV-1 CA–NCprotein and, in some cases, GADPH. The PELLET from the 70% cushionwas analyzed byWestern blotting using antibodies against the V5 tag andHIV-
1 CA–NC protein. The effect of adding cyclosporine A (CsA) to the mixture of TRIMCyp-containing cell lysate and CA–NC complexes is shown in panel A. In panels
B, C, and D, the binding of the indicated TRIMCyp mutants to the HIV-1 CA–NC complexes is examined. In panel E, the binding of the pure bacterially expressed
thioredoxin-TRIMCyp fusion protein [HP-Thio-TRIMCyp(V5)] to in vitro assembled HIV-1 CA–NC complexes in the presence or absence of CsA is shown.
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TRIM5, which encodes the presumably beneficial retroviral
restriction factor TRIM5α. This observation implies that
TRIMCyp is beneficial to owl monkeys, perhaps more so
than TRIM5α. A puzzling aspect of this expectation is that the
only virus known to be restricted by TRIMCyp is HIV-1, which
is unlikely to have imposed selective pressure on Aotus
lineages. Here, we show that several other retroviruses, SIVagm
and FIV, are susceptible to TRIMCyp-mediated restriction.
Thus, it is probable that, during owl monkey evolution, the
expression of TRIMCyp conferred resistance to infection by
retroviruses.
The abrogation of TRIMCyp restriction of HIV-1, SIVagm
and FIV restriction by cyclosporine A implies that the
cyclophilin A moiety of TRIMCyp must functionally interact
with viral components. For HIV-1, escape from TRIMCyp-
mediated suppression can be achieved by alteration of capsid
residues 89 and 90, a glycine-proline pair that is known to
contact cyclophilin A (Gamble et al., 1996; Vajdos et al.,
1997). Cyclophilin A binding to the HIV-1 capsid has been
suggested to exert positive, but as yet poorly understood,
effects on virus infection (Hatziioannou et al., 2005; Sayah
and Luban, 2004; Gatanaga et al., 2006). Perhaps other
viruses besides HIV-1 naturally interact with cyclophilin A
and thus are rendered susceptible to TRIMCyp restriction in
owl monkey cells. Indeed, an inspection of the primary
sequences of retroviral capsids reveals the existence of
glycine-proline motifs in several lentiviral capsids, in regions
analogous to the cyclophilin A-binding loop of HIV-1 (Fig.
8). The exact requirements for susceptibility to TRIMCyp-
mediated restriction require further investigation; the mere
presence of a glycine-proline motif in a surface-exposed
capsid loop is not sufficient for TRIMCyp restriction, as
evidenced by equine infectious anemia virus (Fig. 8) (Jin et
al., 1999).
Cyclophilin A can interact with the monomeric p24 capsid
protein of HIV-1 with low affinity (Gamble et al., 1996;
Vajdos et al., 1997; Yoo et al., 1997). TRIMCyp has also
been reported to exhibit some binding to HIV-1 capsid
proteins, although no estimation of the affinity of this
interaction was attempted (Nisole et al., 2004). The natural
target for TRIMCyp and TRIM5α is the assembled, mature
viral capsid (Dodding et al., 2005; Forshey et al., 2005).
Recently, we have demonstrated a specific interaction
between TRIM5α variants and in vitro assembled HIV-1
CA–NC complexes such as those used in this study (Stremlau
et al., in press). The efficient TRIM5α-capsid interaction is
dependent on conditions that preserve the integrity and three-
dimensional architecture of the HIV-1 capsid. It is likely that
TRIM5α trimerization contributes to the avidity of interaction
with retroviral capsids, which exhibit trimeric pseudosymme-
try (Ganser et al., 1999; Li et al., 2000). Here, we show that
TRIMCyp also interacts with HIV-1 CA–NC complexes
assembled in vitro. This interaction is inhibitable by
cyclosporine A and is dependent on the integrity of the
coiled-coil and cyclophilin A domains of TRIMCyp. Notably,
the cyclophilin A moiety of TRIMCyp alone did not bindefficiently to the HIV-1 CA–NC complexes, supporting the
contribution of TRIMCyp oligomerization to the avidity of
capsid interaction.
One notable difference between TRIMCyp and TRIM5α
binding to the HIV-1 CA–NC complexes is that the linker
between the coiled coil and the C-terminal domain is
dispensable for TRIMCyp, but not for TRIM5α, binding
(Stremlau et al., in press). This linker may influence the
spatial relationships between the TRIMCyp and TRIM5α
carboxy-terminal domains and the trimer axis. Such spacing
may be less critical for the cyclophilin A moiety of
TRIMCyp, which interacts with potentially flexible surface-
exposed loops on the capsid, than for the TRIM5α B30.2
(SPRY) domain, which is hypothesized to interact with rigid,
recessed holes on the capsid surface (Mische et al., 2005).
The linker region might allow each of the three B30.2(SPRY)
domains of TRIM5α to engage their respective pockets on the
capsid surface.
Importantly, we demonstrate that the amino-terminal
TRIMCyp domains, although contributing to the antiretroviral
function of TRIMCyp, are not required for efficient interaction
with the HIV-1 CA–NC complex. Consistent with the possible
contribution of TRIMCyp oligomerization to capsid-binding
avidity, neither the RING domain nor the B-box 2 domain is
required for the trimerization of TRIMCyp. Apparently,
TRIMCyp mutants with defective or missing RING and B-
box 2 domains can bind capsids but do not negotiate an
effector function critical for interference with the infection
pathway. TRIMCyp mutants with altered RING or B-box 2
domains were at least partially located in the cytoplasm.
Therefore, if the effector function dictates proper location in
the cell, it must determine a more specific cytoplasmic
compartment. Other possibilities for “effector” functions
include particular types of self-association or association
with cofactors.
Both TRIMCyp and TRIM5α restrict retrovirus infection
soon after the entry of the viral capsid into the cytosol (Perez-
Caballero et al., 2005). Even the earliest step in reverse
transcription, the formation of strong-stop cDNA, does not
occur efficiently in cells expressing the restricting protein.
The mechanism of TRIMCyp restriction clearly involves
some action directed towards the viral capsid. Of interest, it
has been observed that the binding of excess cyclophilin A
can be detrimental to HIV-1 infection (Gatanaga et al., 2006).
Indeed, we observed a mild negative effect on HIV-1
infection of expression of TRIMCyp Δ245, which consists
only of the linker region and the cyclophilin A moiety. The
increase in capsid-binding avidity resulting from TRIMCyp
oligomerization could result in unfavorable levels of the
cyclophilin A moiety bound to the HIV-1 capsid. However,
only when RING and B-box 2 domains are intact does the
full level of restriction ensue. Defining the effector function
should advance our understanding of TRIMCyp-mediated
restriction.
Of interest, cyclosporine A treatment of canine cells
transduced with the empty control vector significantly increased
the ability of FIV to infect these cells. This observation raises
Fig. 8. Alignment of the sequences of putative cyclophilin A-binding loops on some lentivirus capsids. The primary sequences of several lentivirus capsids in the
region carboxy-terminal to the α4 helix are aligned. The residue numbers correspond to those of the HIV-1HXBc2 capsid. Note that several lentiviruses have a glycine-
proline motif (highlighted) at a position similar to that of the known cyclophilin A-binding site of the HIV-1 capsid (Gamble et al., 1996; Vajdos et al., 1997; Yoo et al.,
1997). FIV strains have either a glycine-proline or an alanine-proline pair at this site. smm = sooty mangabey; stm = stump-tailed macaque; agm = African green
monkey; rcm = red-capped mangabey.
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dependent factor exerts a negative effect on FIV infection. Our
understanding of such host factors may suggest strategies for
intervention in retroviral infections.
Materials and methods
Plasmid construction
The plasmids expressing the wild-type and mutant TRIM-
Cyp proteins tagged with a carboxy-terminal hemagglutinin
(HA) epitope were constructed using PCR. The TRIMCyp
cDNA was PCR-amplified and digested with EcoRI and ClaI,
whose sites were introduced by inclusion in each of the PCR
primers. These fragments were cloned into the EcoRI and ClaI
site of pLPCX (Stratagene). The plasmids expressing wild-type
and mutant TRIMCyp tagged with a carboxy-terminal V5
epitope were constructed by inserting a PCR-amplified
TRIMCyp cDNA into the Viral Power plasmid using directional
TOPO cloning (Invitrogen).
Cells and drugs
HeLa epithelial cells and Cf2Th canine thymocytes were
obtained from ATCC. A 10 mM stock solution of cyclosporine
A (Sigma) in ethanol was used to achieve a final concentration
of 5 μM in cell media.Creation of cells stably expressing TRIMCyp variants
Retroviral vectors encoding wild-type or mutant TRIMCyp
proteins were created using the pLPCX vector. Recombinant
viruses were produced in 293T cells by cotransfecting the
pLPCX plasmids with the pVPack-GP and pVPack-VSV-G
packaging plasmids (Stratagene). The pVPack-VSV-G plasmid
encodes the vesicular stomatitis virus (VSV) G envelope
glycoprotein, which allows efficient entry into a wide range
of vertebrate cells. Transduced cells were selected in 1 μg/ml
puromycin (Sigma).
Recombinant lentiviruses expressing wild-type and mutant
TRIMCyp-V5 proteins were made using the Viral Power system
(Invitrogen) according to the manufacturer's protocol. The
resulting virus particles were used to transduce approximately
1 × 106 HeLa cells in the presence of 5 μg/ml polybrene.
Transduced cells were selected in 2 μg/ml blasticidin (Invitro-
gen). Cell lines expressing both wild-type and mutant
TRIMCyp proteins were obtained by transduction with both
LPCX and Viral Power vectors and dual selection with
puromycin and blasticidin.
Infection with viruses expressing green fluorescent protein
(GFP)
Recombinant HIV-1, SIVmac and SIVagm expressing GFP
were prepared as described (Stremlau et al., 2004). Viral stocks
416 F. Diaz-Griffero et al. / Virology 351 (2006) 404–419were quantified by measuring reverse transcriptase (RT)
activity. For infections, 3 × 104 HeLa or Cf2Th cells seeded
in 24-well plates were incubated with virus for 24 h. Cells were
washed and returned to culture for 48 h and then subjected to
FACS analysis with a FACScan (Becton Dickinson). The feline
immunodeficiency virus (FIV) vector was obtained from
System Biosciences (Mountain View, CA) and was prepared
following the manufacturer's instructions. The equine infec-
tious anemia virus (EIAV) vector was a gift from Dr. John Olsen
(1998). FIV and EIAV viral stocks were titrated by serial
dilution on Cf2Th cells.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipita-
tion assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM NaCl;
1% sodium deoxycholate; 0.1% sodium dodecyl sulfate [SDS];
1% NP-40; 2 mg/ml aprotinin; 2 mg/ml leupeptin; 1 mg/ml
pepstatin A; 100 mg/ml phenylmethylsulfonyl fluoride). The
cell lysates were analyzed by SDS-PAGE (10% acrylamide),
followed by blotting onto nitrocellulose membranes (Amer-
sham Pharmacia Biotech). Detection of protein by Western
blotting utilized monoclonal antibodies directed against the HA
(Roche) or V5 (Invitrogen) epitope tags and monoclonal
antibodies to β-actin (Sigma). Detection of proteins was
performed by enhanced chemiluminescence (NEN Life
Sciences Products), using antimouse (for V5 and β-actin) and
antirat (for HA) secondary antibodies (Amersham Pharmacia
Biotech).
TRIMCyp localization experiments
Localization of TRIMCyp variants in expressing cells was
investigated as previously described (Diaz-Griffero et al.,
2002). Briefly, cells were grown overnight on 12-mm-diameter
coverslips and fixed in 3.9% paraformaldehyde (Sigma) in
phosphate-buffered saline (PBS; Cellgro) for 30 min. Cells were
washed in PBS, incubated in 0.1 M glycine (Sigma) for 10 min,
washed in PBS, and permeabilized with 0.05% saponin (Sigma)
for 30 min. Samples were blocked with 10% donkey serum
(Dako, Carpinteria, CA) for 30 min, and incubated for 1 h with
antibodies. The anti-HA FITC-conjugated 3F10 antibody
(Roche) was used to stain HA-tagged TRIM5Cyp proteins,
respectively. Subsequently, samples were mounted for fluores-
cence microscopy by using the ProLong Antifade Kit
(Molecular Probes, Eugene, OR). Images were obtained with
a BioRad Radiance 2000 laser scanning confocal microscope
with Nikon 60× N.A.1.4 optics.
Immunoprecipitations
At 48 h after transfection, 293T cells were removed from
the plate and washed with PBS. 293T cells from nearly
confluent 100-mm plates were lysed in 500 μl IP buffer
(50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM DTT,
0.5% NP-40, Protease Inhibitor Cocktail). Insoluble material
was pelleted at 22,000 × g for 2 hours and the supernatantwas used for immunoprecipitation. Equal amounts of protein
(approximately 200–500 μg, as determined by the BioRad
assay) were incubated with 30 μl protein A-Sepharose (50%)
and 5 μl of anti-HA antibody (Roche) for 2 hours at 4 °C.
The precipitates were then washed three times with IP buffer
and twice with PBS. After the final supernatant was
removed, 30 μl of 2× sample buffer (120 mM Tris–HCl,
pH 6.8, 20% glycerol, 4% SDS, and 0.02% bromphenol
blue) was added, and the samples were boiled for 5 min.
Supernatants were loaded on SDS-polyacrylamide gels and
analyzed by Western blotting using anti-HA or anti-V5
antibodies.
HIV-1 luciferase reporter virus
The plasmid pNLX.Luc(R-) and the expression vector
encoding vesicular stomatitis virus G (VSV-G) glycoprotein
(pVSV-G) have been previously described (Lu et al., 2004).
Single-round viruses carrying the VSV-G envelope glycoprotein
were derived by co-transfecting 293T cells with pNLX.Luc(R-)
and pVSV-G at the ratio of 10:1 in the presence of calcium
phosphate. Culture supernatants were collected 36 h after
transfection, filtered through 0.45-μm-diameter pores, and
treated for 1 h at 37 °C with 40 U/ml Turbo DNase (Ambion)
prior to use. Cell-free virus titers were determined with an
exogenous 32P-based reverse transcriptase assay. Twenty-four
hours prior to infection, cells (2 × 105/well) were plated in 6-
well trays. For infections with recombinant viruses, cells were
incubated with 1 × 106 (Luciferase assays) or 5 × 106 (DNA
assays) cpm of RT activity in a final volume of 500 μl for 2 h.
Medium was then added to a final volume of 2 ml, and the
cells were cultured until harvesting. At 48 h after infection,
cells were washed once in PBS and then lysed in 150 μl of
Passive Lysis Buffer (Promega Corp.). Cell lysates were
centrifuged at 20,630×g for 15 min at 4 °C to pellet debris,
diluted 1:100 in Passive Lysis Buffer, and then 20 μl was
analyzed using the Luciferase Assay Reporter System
(Promega Corp.) as recommended by the manufacturer.
Luciferase values were normalized to the total protein content
of extracts as determined by the Bio-Rad Protein Assay (Bio-
Rad Laboratories).
Real-time PCR
Extrachromosomal HIV-1 DNA was extracted from cells
following infection as previously described (Vandegraaff
et al., 2001) and DNA resuspended at approximately 6000
cell equivalents/μl (c.e./μl). Relative levels of total DNA
in extracts were determined by amplification of mitochon-
drial DNA sequences using a semi-quantitative real-time
PCR (qPCR). Primers for amplification of mitochondrial
DNA (designed to amplify both canine and human sequen-
ces) were 5′-GGGATAACAGCGCAATCCTATTC and 5′-
ACGTAGGACTTTAATCGTTGAAC.
PCR reactions (30 μl) were performed using the QuantiTect
Sybr Green PCR Kit (Qiagen) under conditions recommended
by the manufacturer. Reactions were cycled as follows: 95 °C
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s, and 72 °C for 30 s. Melting curve analyses (from 55 °C to 90
°C, read every 1 °C) were conducted to confirm amplification of
predominantly a single DNA species. PCR reactions assessing
strong-stop and late reverse transcription products were
performed using primers and probes as previously described
(Julias et al., 2001; Butler et al., 2001). PCR reactions (30 μl)
were performed using the QuantiTect Probe PCR Kit (Qiagen)
under conditions recommended by the manufacturer. Reactions
were cycled as follows: 50 °C for 2 min, 95 °C for 10 min,
followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
Serial dilutions of known amounts of plasmid pNLX.Luc(R-)
served as a copy number standard to generate standard curves.
PCR reactions were performed in a DNA Engine Opticon
thermal cycler (MJ Research Inc., Waltham, Mass), and results
were analyzed using the OpticonMONITOR Analysis Software
version 2.01 supplied by the manufacturer.
TRIMCyp cross-linking assay
Approximately 1 × 107 293T cells transfected with 5 μg of
plasmids expressing TRIMCyp variants were lysed in IP buffer
and cross-linked with different concentrations (0–5 mM) of
glutaraldehyde for 5 min as previously described (Mische et al.,
2005). After cross-linking, samples were taken up in 2× sample
buffer and incubated at 37 °C for 30 min. Samples were
analyzed by SDS-PAGE and Western blotting with an anti-V5
antibody (Invitrogen).
HIV CA–NC expression and purification
HIV-1 CA–NC protein was expressed, purified, and
assembled as previously described (Ganser et al., 1999). The
pET11a expression vector (Novagen) expressing CA–NC of
HIV-1 was used to transform BL-21(DE3). CA–NC expression
was induced with 1 mM isopropyl-beta-D-thiogalactopyrano-
side (IPTG) when cells achieved an optical density at 600 nm of
0.6. After 4 h of induction, cells were harvested and
resuspended in 20 mM Tris–HCl (pH 7.5), 1 μM ZnCl2,
10 mM 2-mercaptoethanol and protease inhibitors (Roche).
Bacteria were lysed by sonication and debris was pelleted for
30 min at 35,000×g. Nucleic acids were stripped from the
solution by using 0.11 equivalents of 2 M (NH4)2SO4 and the
same volume of 10% polyethyleneimine. Nucleic acids were
removed by stirring and centrifugation at 29,500×g for 15 min.
Protein was recovered by addition of 0.35 equivalents of
saturated (NH4)2SO4. Protein was centrifuged at 9820×g for
15 min and resuspended in 100 mM NaCl, 20 mM Tris–HCl
(pH 7.5), 1 μM ZnCl2 and 10 mM 2-mercaptoethanol. Protein
was dialyzed against 50 mM NaCl, 20 mM Tris–HCl (pH 7.5),
1 μM ZnCl2, and 10 mM 2-mercaptoethanol.
In vitro assembly of HIV-1 capsid complexes
HIV-1 capsid complexes were assembled in vitro by diluting
the HIV-1 CA–NC protein to a concentration of 0.3 mM in
50 mM Tris–HCl (pH 8.0), 0.5 M NaCl and 2 mg/ml DNAoligo (TG)50. The mixture was incubated at 4 °C overnight and
centrifuged at 8600×g for 5 min. The pellet was resuspended in
assembly buffer (50 mM Tris–HCl (pH 8.0), 0.5 M NaCl) at a
final protein concentration of 0.15 mM (Ganser-Pornillos et al.,
2004).
TRIMCyp binding to HIV-1 CA–NC complexes
293T cells were transfected with plasmids expressing
different TRIMCyp or TRIM5 proteins. Forty-eight hours
after transfection, cell lysates were prepared as follows: Washed
cells were resuspended in hypotonic lysis buffer (10 mM Tris,
pH 7.4, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT). The cell
suspension was frozen and thawed and then incubated on ice for
10 min. Afterwards, the lysate was centrifuged at 14,000×g in a
refrigerated microcentrifuge for 5 min. The supernatant was
supplemented with 1/10 volume of 10× PBS and then used in
the binding assay. Five milliliters of in vitro assembled CA
particles were incubated with 200 μl of cell lysate at room
temperature for 1 h. A fraction of this mixture was stored
(INPUT). The remainder of the mixture was spin through a 70%
sucrose cushion (70% sucrose, 1× PBS and 0.5 mM DTT) at
100,000×g in an SW55 rotor (Beckman) for 1 h at 4 °C. After
centrifugation, the supernatant was carefully removed, and the
pellet was resuspended in 1× SDS-PAGE loading buffer
(PELLET). The level of TRIMCyp or TRIM5 proteins was
determined by Western blot.
TRIMCyp expression in E. coli
Owl monkey TRIMCyp was cloned in the pBAD vector
following the manufacturer's directions (pBAD/TOPO ThioFu-
sion, Invitrogen). This vector fused a Histidine patch thior-
edoxin to the amino terminus of TRIMCyp and a V5-6His tag at
the carboxyl terminus. DH5α cells were transformed, and
expression was induced by using 0.2% L-arabinose. Induction
was performed at an optical density (OD600) of 0.6 for 5 h. Cells
were harvested and lysed by sonication in Buffer A [200 mM
NaCl, 50 mM Tris–HCl (pH 8.0), 1 mM DTT and protease
inhibitors (Roche)]. The lysate was centrifuged at 15,000 rpm
in a JA-10 rotor (Beckman). The pellet was washed twice in
buffer A containing 0.5% Triton X-100 and twice in buffer A
containing 2 M urea. The remaining pellet was dissolved in
buffer A containing 8 M urea. Supernatant was diluted 1/10 in
buffer A and purified by using a Ni-NTA resin (Qiagen). Protein
was eluted by using buffer A in 200 mM imidazole. Two
dialysis steps against buffer Awere performed. The thioredoxin-
TRIMCyp protein was snap frozen in liquid nitrogen and stored
at −80 °C. The thioredoxin-TRIMCyp protein was estimated to
be 90% pure by Coomassie staining of SDS-polyacrylamide
gels.
Acknowledgments
We thank Ms. Yvette McLaughlin and Sheri Farnum for
manuscript preparation, and the National Institutes of Health
(AI063987, HL54785, AI45405, and a Center for AIDS
418 F. Diaz-Griffero et al. / Virology 351 (2006) 404–419Research Award [AI28691]), the International AIDS Vaccine
Initiative, the Bristol-Myers Squibb Foundation, the William A.
Haseltine Foundation for the Arts and Sciences, and the late
William F. McCarty-Cooper for financial support. M.S. was
supported by a National Defense Science and Engineering
Fellowship and is a Fellow of the Ryan Foundation.
References
Aiken, C., 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1)
by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an
endocytic pathway and suppresses both the requirement for Nef and the
sensitivity to cyclosporin A. J. Virol. 71, 5871–5877.
Besnier, C., Takeuchi, Y., Towers, G., 2002. Restriction of lentivirus in
monkeys. Proc. Natl. Acad. Sci. U.S.A. 99, 11920–11925.
Bosco, D.A., Kern, D., 2004. Catalysis and binding of cyclophilin A with
different HIV-1 capsid constructs. Biochemistry 43, 6110–6119.
Bosco, D.A., Eisenmesser, E.Z., Pochapsky, S., Sundquist, W.I., Kern, D., 2002.
Catalysis of cis/trans isomerization in native HIV-1 capsid by human
cyclophilin A. Proc. Natl. Acad. Sci. U.S.A. 99, 5247–5252.
Butler, S.L., Hansen, M.S., Bushman, F.D., 2001. A quantitative assay for HIV
DNA integration in vivo. Nat. Med. 7, 631–634.
Chatterji, U., Bobardt, M.D., Stanfield, R., Ptak, R.G., Pallansch, L.A., Ward,
P.A., Jones, M.J., Stoddard, C.A., Scalfaro, P., Dumont, J.M., Besseghir,
K., Rosenwirth, B., Gallay, P.A., 2005. Naturally occurring capsid
substitutions render HIV-1 cyclophilin A independent in human cells and
TRIM-cyclophilin-resistant in Owl monkey cells. J. Biol. Chem. 280,
40293–40300.
Cowan, S., Hatziioannou, T., Cunningham, T., Muesing, M.A., Gottlinger, H.G.,
Bieniasz, P.D., 2002. Cellular inhibitors with Fv1-like activity restrict
human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci.
U.S.A. 99, 11914–11919.
Diaz-Griffero, F., Hoschander, S.A., Brojatsch, J., 2002. Endocytosis is a critical
step in entry of subgroup B avian leukosis viruses. J. Virol. 76,
12866–12876.
Dodding, M.P., Bock, M., Yap, M.W., Stoye, J.P., 2005. Capsid processing
requirements for abrogation of Fv1 and Ref1 restriction. J. Virol. 79,
10571–10577.
Forshey, B.M., Shi, J., Aiken, C., 2005. Structural requirements for recognition
of the human immunodeficiency virus type 1 core during host restriction in
owl monkey cells. J. Virol. 79, 869–875.
Gamble, T.R., Vajdos, F.F., Yoo, S., Worthylake, D.K., Houseweart, M.,
Sundquist, W.I., Hill, C.P., 1996. Crystal structure of human cyclophilin A
bound to the amino-terminal domain of HIV-1 capsid. Cell 87, 1285–1294.
Ganser-Pornillos, B.K., von Schwedler, U.K., Stray, K.M., Aiken, C.,
Sundquist, W.I., 2004. Assembly properties of the human immunodeficien-
cy virus type 1 CA protein. J. Virol. 78, 2545–2552.
Ganser, B.K., Li, S., Klishko, V.Y., Finch, J.T., Sundquist, W.I., 1999. Assembly
and analysis of conical models for the HIV-1 core. Science 283, 80–83.
Gatanaga, H., Das, D., Suzuki, Y., Yeh, D.D., Hussain, K.A., Ghosh, A.K.,
Mitsuya, H., 2006. Altered HIV-1 gag interactions with cyclophilin A (Cyp
A) upon acquisition of H219G and H219P substitutions in the Cyp A
binding loop. J. Biol. Chem. (electonic publication ahead of print).
Hatziioannou, T., Cowan, S., Goff, S.P., Bieniasz, P.D., Towers, G.J., 2003.
Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22,
385–394.
Hatziioannou, T., Perez-Caballero, D., Yang, A., Cowan, S., Bieniasz, P.D.,
2004a. Retrovirus resistance factors Ref1 and Lv1 are species-specific
variants of TRIM5alpha. Proc. Natl. Acad. Sci. U.S.A. 101, 10774–10779.
Hatziioannou, T., Cowan, S., Von Schwedler, U.K., Sundquist, W.I., Bieniasz, P.
D., 2004b. Species-specific tropism determinants in the human immunode-
ficiency virus type 1 capsid. J. Virol. 78, 6005–6012.
Hatziioannou, T., Perez-Caballero, D., Cowan, S., Bieniasz, P.D., 2005.
Cyclophilin interactions with incoming human immunodeficiency virus
type 1 capsids with opposing effects on infectivity in human cells. J. Virol.
79, 176–183.Hofmann, W., Schubert, D., LaBonte, J., Munson, L., Gibson, S., Scammell,
J., Ferrigno, P., Sodroski, J., 1999. Species-specific, postentry barriers to
primate immunodeficiency virus infection. J. Virol. 73, 10020–10028.
Javanbakht, H., Diaz-Griffero, F., Stremlau, M., Si, Z., Sodroski, J., 2005. The
contribution of RING and B-box 2 domains to retroviral restriction mediated
by monkey TRIM5α. J. Biol. Chem. 280, 26933–26940.
Jin, Z., Jin, L., Peterson, D.L., Lawson, C.L., 1999. Model for lentivirus capsid
core assembly based on crystal dimers of EIAV p26. J. Mol. Biol. 286,
83–93.
Julias, J.G., Ferris, A.L., Boyer, P.L., Hughes, S.H., 2001. Replication of
phenotypically mixed human immunodeficiency virus type 1 virions
containing catalytically active and catalytically inactive reverse transcrip-
tase. J. Virol. 75, 537–546.
Keckesova, Z., Ylinen, L.M., Towers, G.J., 2004. The human and African green
monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction
factor activities. Proc. Natl. Acad. Sci. U.S.A. 101, 10780–10785.
Kootstra, N.A., Munk, C., Tonnu, N., Landau, N.R., Verma, I.M., 2003.
Abrogation of postentry restriction of HIV-1-based lentiviral vector
transduction in simian cells. Proc. Natl. Acad. Sci. U.S.A. 100,
1298–1303.
Li, S., Hill, C.P., Sundquist, W.I., Finch, J.T., 2000. Image reconstructions of
helical assemblies of the HIV-1 CA protein. Nature 407, 409–413.
Lu, R., Limon, A., Devroe, E., Silver, P.A., Cherepanov, P., Engelman, A.,
2004. Class II integrase mutants with changes in putative nuclear
localization signals are primarily blocked at a postnuclear entry step of
human immunodeficiency virus type 1 replication. J. Virol. 78,
12735–12746.
Luban, J., Bossolt, K.L., Franke, E.K., Kalpana, G.V., Goff, S.P., 1993. Human
immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.
Cell 73, 1067–1078.
Matlin, K.S., Reggio, H., Helenius, A., Simons, K., 1982. Pathway of
vesicular stomatitis virus entry leading to infection. J. Mol. Biol. 156,
609–631.
Mische, C.C., Javanbakht, H., Song, B., Diaz-Griffero, F., Stremlau, M., Strack,
B., Si, Z., Sodroski, J., 2005. Retroviral restriction factor TRIM5alpha is a
trimer. J. Virol. 79, 14446–14450.
Munk, C., Brandt, S.M., Lucero, G., Landau, N.R., 2002. A dominant block to
HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad.
Sci. U.S.A. 99, 13843–13848.
Nakayama, E.E., Miyoshi, H., Nagai, Y., Shioda, T., 2005. A specific region of
37 amino acid residues in the SPRY (B30.2) domain of African green
monkey TRIM5alpha determines species-specific restriction of simian
immunodeficiency virus SIVmac infection. J. Virol. 79, 8870–8877.
Nisole, S., Lynch, C., Stoye, J.P., Yap, M.W., 2004. A Trim5-cyclophilin A
fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc.
Natl. Acad. Sci. U.S.A. 101, 13324–13328.
Nisole, S., Stoye, J.P., Saib, A., 2005. TRIM family proteins: retroviral
restriction and antiviral defence. Nat. Rev., Microbiol. 3, 799–808.
Olsen, J.C., 1998. Gene transfer vectors derived from equine infectious anemia
virus. Gene Ther. 5, 1481–1487.
Owens, C.M., Yang, P.C., Gottlinger, H., Sodroski, J., 2003. Human and
simian immunodeficiency virus capsid proteins are major viral determi-
nants of early, postentry replication blocks in simian cells. J. Virol. 77,
726–731.
Owens, C.M., Song, B., Perron, M.J., Yang, P.C., Stremlau, M., Sodroski, J.,
2004. Binding and susceptibility to postentry restriction factors in monkey
cells are specified by distinct regions of the human immunodeficiency virus
type 1 capsid. J. Virol. 78, 5423–5437.
Perez-Caballero, D., Hatziioannou, T., Zhang, F., Cowan, S., Bieniasz, P.D.,
2005. Restriction of human immunodeficiency virus type 1 by TRIM-
CypA occurs with rapid kinetics and independently of cytoplasmic bodies,
ubiquitin, and proteasome activity. J. Virol. 79, 15567–15572.
Perron, M.J., Stremlau, M., Song, B., Ulm, W., Mulligan, R.C., Sodroski, J.,
2004. TRIM5alphamediates the postentry block toN-tropicmurine leukemia
viruses in human cells. Proc. Natl. Acad. Sci. U.S.A. 101, 11827–11832.
Ribeiro, I.P., Menezes, A.N., Moreira, M.A., Bonvicino, C.R., Seuanez, H.N.,
Soares, M.A., 2005. Evolution of cyclophilin A and TRIMCyp retro-
transposition in New World primates. J. Virol. 79, 14998–15003.
419F. Diaz-Griffero et al. / Virology 351 (2006) 404–419Sawyer, S.L., Wu, L.I., Emerman, M., Malik, H.S., 2005. Positive selection
of primate TRIM5alpha identifies a critical species-specific retroviral
restriction domain. Proc. Natl. Acad. Sci. U.S.A. 102, 2832–2837.
Sayah, D.M., Luban, J., 2004. Selection for loss of Ref1 activity in human cells
releases human immunodeficiency virus type 1 from cyclophilin A
dependence during infection. J. Virol. 78, 12066–12070.
Sayah, D.M., Sokolskaja, E., Berthoux, L., Luban, J., 2004. Cyclophilin A
retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.
Nature 430, 569–573.
Sebastian, S., Luban, J., 2005. TRIM5alpha selectively binds a restriction-
sensitive retroviral capsid. Retrovirology 2, 40.
Seglen, P.O., 1983. Inhibitors of lysosomal function. Methods Enzymol. 96,
737–764.
Song, B., Javanbakht, H., Perron, M., Park, D.H., Stremlau, M., Sodroski, J.,
2005. Retrovirus restriction by TRIM5alpha variants from Old World and
New World primates. J. Virol. 79, 3930–3937.
Stremlau, M., Owens, C.M., Perron, M.J., Kiessling, M., Autissier, P., Sodroski,
J., 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1
infection in Old World monkeys. Nature 427, 848–853.
Stremlau, M., Perron, M., Welikala, S., Sodroski, J., 2005. Species-specific
variation in the B30.2(SPRY) domain of TRIM5alpha determines the
potency of human immunodeficiency virus restriction. J. Virol. 79,
3139–3145.Stremlau, M., Perron, M., Lee, M., Yuan, L., Song, B., Javanbakht, H., Diaz-
Griffero, F., Anderson, D.J., Sundquist, W.I., Sodroski, J., in press. Specific
recognition and accelerated uncoating of retroviral capsids by the TRIM5
(restriction factor. Proc. Natl. Acad. Sci. U.S.A.
Towers, G.J., Hatziioannou, T., Cowan, S., Goff, S.P., Luban, J., Bieniasz, P.D.,
2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction
factors. Nat. Med. 9, 1138–1143.
Vajdos, F.F., Yoo, S., Houseweart, M., Sundquist, W.I., Hill, C.P., 1997. Crystal
structure of cyclophilin A complexed with a binding site peptide from the
HIV-1 capsid protein. Protein Sci. 6, 2297–2307.
Vandegraaff, N., Kumar, R., Burrell, C.J., Li, P., 2001. Kinetics of human
immunodeficiency virus type 1 (HIV) DNA integration in acutely infected
cells as determined using a novel assay for detection of integrated HIV
DNA. J. Virol. 75, 11253–11260.
Yap, M.W., Nisole, S., Lynch, C., Stoye, J.P., 2004. Trim5alpha protein restricts
both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. U.S.A. 101,
10786–10791.
Yap, M.W., Nisole, S., Stoye, J.P., 2005. A single amino acid change in the
SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr. Biol.
15, 73–78.
Yoo, S., Myszka, D.G., Yeh, C., McMurray, M., Hill, C.P., Sundquist, W.I.,
1997. Molecular recognition in the HIV-1 capsid/cyclophilin A complex.
J. Mol. Biol. 269, 780–795.
